Advanced Prostate Cancer VL

Preview of the Advanced Prostate Cancer Consensus Conference 2019 (APCCC) - Silke Gillessen and Aurelius Omlin

Details
Silke Gillessen, MD and Aurelius Omlin, MD discuss the inception of the biennial Advanced Prostate Cancer Consensus Conference (APCCC) which will be held in Basel this August. The intent of the meeting is to drive international consensus on key areas of prostate cancer practice where there are no clear guidelines or level 1 evidence. 75% of the panelists must agree on each topic to reach a consens...

Prevalence of Germline Variants in Prostate Cancer and Implications for Current Genetic Testing Guidelines - Oliver Sartor

Details
Oliver Sartor, MD discusses his contributions to the recent publication in JAMA Oncology on the prevalence of germline variants in prostate cancer and the implications for genetic testing guidelines. 3600 patients had various forms of germiline genetic testing performed and were available for this analysis. In the dataset, 17% of patients had germline variants and 30% of those were BRCA1/BRCA2. In...

Biomarkers Across the Spectrum of Prostate Cancer- Anis Hamid and Chris Sweeney

Details
Anis Hamid and Chris Sweeney discuss their recent work studying biomarkers across the full spectrum of prostate cancer. Based on preclinical studies we understand that aggressive disease lies in the tumor genome and we see recurrent losses of certain genes in both early and advanced prostate cancer. The classic tumor suppressors that are commonly mutated across cancers, including prostate cancer,...

Integrating Genomics into Localized Prostate Cancer - Todd Morgan and Dan Spratt

Details
Dan Spratt and Todd Morgan discuss the role of genomics in localized prostate cancer from the perspective of the radiation oncologist and the urologist. Based on the MUSIC registry, which represents over 90% of the urology practices across Michigan, they reveal that most of the prostate cancer patients are not receiving genomic profiling. Drs. Spratt and Morgan review each of the genomic tests inc...

Practice Patterns of Active Surveillance in Prostate Cancer - Matt Cooperberg

Details
Alicia Morgans and Matt Cooperberg discuss the current state of contemporary active surveillance and efforts to standardize strategies nationwide. This conversation also includes discussion on informed decision making and practice patterns of active surveillance and how to tailor based on biology and genetics Biographies: Matthew Cooperberg, MD, MPH, FACS, Associate Professor, Department of Urolog...

Challenges in the Treatment of Localized Prostate Cancer - Srikala Sridhar

Details
Kala Sridhar and Alicia Morgans share in a discussion on challenges and opportunities in the treatment of localized prostate cancer from the viewpoint of a medical oncologist. Conversation includes approaches for optimizing systemic therapy in localized disease and new hormonal agents, and the ICECAP initiative. Biographies: Srikala (Kala) Sridhar MD, MSc, FRCPC Medical Advisory and Research Board...

3D Prostate Gland Uptake of 18F Choline PET CT - Association with Overall Survival in Patients with Hormone-naive Prostate Cancer - May Sadik

Details
Dr. May Sadik presents data from the SNMMI meeting highlighting a retrospective study in 45 patients with hormone naïve prostate cancer. The objective was to develop a completely automated method to quantify prostate gland update of 18F-choline in PET/CT images. The hope is that these preliminary data will lead to a better understanding of the relationship between this measure, the clinical data a...

18F Fluorocholine PET-Whole Body MR in the Staging of High Risk Prostate Cancer - Ur Metser

Details
Ur Metser a study that was conducted to determine whether integrated 18F-fluorocholine (FCH) PET whole-body MRI (PET/WBMRI) depicts lymph node and distant metastases in patients with high-risk prostate cancer more frequently than does conventional staging. Biography: Ur Metser, MD, FRCPC, Joint Department of Medical Imaging, the University of Toronto Related Content: 18F-Fluorocholine PET Whole-Bo...

68Ga PSMA 11 PET MRI in Intermediate and High Risk Prostate Cancer - Claudia Zacharias

Details
Claudia Zacharias presents Gallium 6 PSMA-11 PET/MR Imaging in Patients with Newly Diagnosed Intermediate- or High-Risk Prostate Cancer, a pilot study evaluating the detection rate for the initial diagnosis of prostate cancer and the metastatic spread for patients in the intermediate and high-risk prostate cancer risk category using 68 Ga-PSMA-11 PET/MR. She reviews the potential role of 68 Ga-PSM...

A Review of Imaging Modalities in Prostate Cancer - Peter Pinto

Details
(Length of Interview: 17 min) Peter Pinto highlights the paradigm shift to the use of new imaging technology for a more accurate diagnosis of prostate cancer. Targeted MRI/Ultrasound (MR/US) guided biopsy vs TRUS biopsy, full body imaging options such as PET, and Axumin® (fluciclovine F 18) as a staging tool, with mention of metabolic and focal imaging are part of this comprehensive interview. As...
E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe